SCHEMBL4869324

SCHEMBL4869324

CC(=O)Nc1ccc2sc3ccc(NC(C)=O)cc3c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
KMT2A Q03164 3/20 0.54
MTNR1A P48039 2/20 0.54
MTNR1B P49286 2/20 0.54
LDHA P00338 2/20 0.53
PSMB8 P28062 1/20 0.53
MAPT P10636 3/20 0.53
G6PD P11413 1/20 0.52
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
PFKFB3 Q16875 1/20 0.49
CA2 P00918 2/20 0.49
MEN1 O00255 2/20 0.49
NPC1 O15118 1/20 0.49
GLA P06280 1/20 0.49
TNNI3 P19429 1/20 0.49
TNNT2 P45379 1/20 0.49
RAB9A P51151 1/20 0.49
TNNC1 P63316 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5106815 0.92 MAPT (0.65) KDM4EKMT2AMTNR1AMTNR1BMAPT
SCHEMBL12278579 0.85 LDHA (0.57) KDM4EKMT2ALDHAPSMB8MAPT
SCHEMBL12922996 0.84 PFKFB3 (0.53) KDM4EKMT2AMTNR1AMTNR1BLDHA
SCHEMBL22281315 0.84 KDM4E (0.68) KDM4EKMT2AMTNR1AMTNR1BMAPT
SCHEMBL15237053 0.84 ALDH1A1 (0.67) KDM4EKMT2AMTNR1AMTNR1BLDHA
SCHEMBL15227155 0.83 ALDH1A1 (0.50) KDM4EKMT2AMTNR1AMTNR1BLDHA
SCHEMBL28124654 0.81 KDM4E (0.55) KDM4EKMT2AMTNR1AMTNR1BLDHA
SCHEMBL11540003 0.81 KDM4E (0.51) KDM4EKMT2AMTNR1AMTNR1BLDHA
SCHEMBL17033113 0.80 SMN1; SMN2 (0.54) KDM4EKMT2AMTNR1AMTNR1BMAPT
SCHEMBL12896169 0.80 KDM4E (0.47) KDM4EKMT2AMTNR1AMTNR1BLDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0342433-A2 Substituted dibenzothiaphenes AMERICAN CYANAMID COMPANY (US) 1989-11-23 EP claimed
US-20080070963-A1 Compositions and methods for promoting neural regeneration Neuberger, Timothy 2008-03-20 US disclosed
US-7271187-B2 Compositions and methods for promoting tissue regeneration Neuberger, Tim (US) 2007-09-18 US disclosed
US-20020055530-A1 Compositions and methods for promoting tissue regeneration URI HERZBERG 2002-05-09 US disclosed
WO-2001076592-A1 COMPOSITIONS AND METHODS FOR PROMOTING NEURAL REGENERATION ACORDA THERAPEUTICS, INC. (US) 2001-10-18 WO disclosed
US-4965284-A IMMUNOMODULATORS AMERICAN CYANAMID COMPANY (US) 1990-10-23 US disclosed
EP-0342433-A2 Substituted dibenzothiaphenes AMERICAN CYANAMID COMPANY (US) 1989-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055530-A1 Compositions and methods for promoting tissue regeneration TST, DCX, GAP43 KDM4E 1417/4885KMT2A 4017/4885MTNR1A 503/4885
US-20080070963-A1 Compositions and methods for promoting neural regeneration GAP43, DCX, BDNF KDM4E 1470/4885KMT2A 4009/4885MTNR1A 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.